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ABSTRACT 
Osteoporosis and ischaemic heart disease represent important public health problems. Existing 
research suggests an association between the two conditions beyond that attributable to shared risk 
factors, with a potentially causal relationship. In this study, we tested the association of speed of 
sound (SOS) from quantitative heel ultrasound with 1) measures of arterial compliance from 
cardiovascular magnetic resonance (aortic distensibility, AD); 2) finger photoplethysmography 
(arterial stiffness index, ASI); and 3) incidence myocardial infarction and ischaemic heart disease 
mortality in the UK Biobank cohort. We considered the potential mediating effect of a range of blood 
biomarkers and cardiometabolic morbidities and evaluated differential relationships by sex, 
menopause status, smoking, diabetes, and obesity. Furthermore, we considered whether associations 
with arterial compliance explained association of SOS with ischaemic cardiovascular outcomes. 
Higher SOS was associated with lower arterial compliance by both ASI and AD for both men and 
women. The relationship was most consistent with ASI, likely relating to larger sample size available 
for this variable (n=159,542 vs n=18,229). There was no clear evidence of differential relationship by 
menopause, smoking, diabetes, or body mass index. Blood biomarkers appeared important in 
mediating the association for both men and women, but with different directions of effect and did not 
fully explain the observed effects. In fully adjusted models, higher SOS was associated with 
significantly lower ischaemic heart disease mortality in men, but not in women. The association of 
SOS with ASI did not explain this association. In conclusion, our findings support a positive 
association between bone and vascular health with consistent patterns of association in men and 
women. The underlying mechanisms are complex and appear to vary by sex. 
 






Osteoporosis is a significant public health problem, particularly in aging populations. In the UK, 
approximately one in three women and one in five men will sustain an osteoporotic fracture in their 
lifetime(1). Ischaemic heart disease is the most common cause of morbidity and mortality in the 
world(2). 
 
Osteoporosis and atherosclerosis share a number of risk factors, such as older age, smoking, and 
sedentary lifestyle. Interestingly, several studies demonstrate an association between the two 
conditions beyond these shared risk factors(3–6). Additionally, biological and genetic studies have 
proposed common mechanisms driving bone mineralisation and atherogenesis(7–9). Overall, there is 
evidence for common causal pathways linking the two disease processes. However, existing literature 
is limited by small sample sizes, lack of objective measures of bone and heart health, and inability to 
adequately consider potential mediators and confounders. Further, whilst sex differential disease 
patterns and the modifying effect of menopause on bone and cardiovascular health are well-
recognised, such distinctions have not been clearly elucidated with regard to relationships between 
these two disease areas. 
 
We studied, in the UK Biobank (UKB), the association of speed of sound (SOS) assessed by 
quantitative heel ultrasound with measures of arterial compliance on cardiovascular magnetic 
resonance (CMR) imaging and finger photoplethysmography. We considered the potential mediating 
effect of a range of blood biomarkers and cardiometabolic morbidities and evaluated differential 
relationships by sex, menopause status, smoking, diabetes, and obesity. Furthermore, we considered 




Setting and recruitment 
UKB is a population study incorporating over half a million participants recruited between 2006-2010 
from across the UK(10). Individuals aged 40-69 years old were identified through National Health 
Service (NHS) registers and invited to participate. The baseline assessment included detailed review 
of demographics, lifestyle, medical history, a series of physical measures, and blood sampling. The 
protocol is publicly available(11). Individuals who were unable to consent or complete baseline 
assessment due to illness or discomfort were not recruited. Linkages with Hospital Episode Statistics 
(HES) and death registers enable longitudinal tracking of health outcomes for all participants. 
Additionally, UKB has produced algorithmically defined outcomes for incidence of key illnesses 
through checks across multiple data sources(12). The UKB Imaging Study, which includes 
cardiovascular magnetic resonance (CMR) imaging, aims to image a subset of 100,000 participants; 
since its launch in 2015, over 48,000 (July 2020) participants have been scanned(13). 
 
Ethics 
This study was covered by the ethical approval for UK Biobank studies from the NHS National 
Research Ethics Service on 17th June 2011 (Ref 11/NW/0382) and extended 10th May 2016 (Ref 
16/NW/0274). 
 
Calcaneal quantitative ultrasound 
Calcaneal quantitative ultrasound (QUS) is a non-invasive and radiation-free method of assessing 
bone quality. QUS parameters are good predictors of fragility fractures and correlate reliably with 
bone mineral density (BMD) measured by DXA (dual-energy x-ray absorptiometry)(14,15). 
 
Calcaneal QUS was performed for the whole UKB cohort at baseline using the Sahara Clinical Bone 
Sonometer (Hologic, USA) according to a predefined standard operating procedure (SOP)(16). Daily 
quality control checks of the sonometer were performed using a phantom. Measurement was not taken 
for individuals with open wounds around the heel or metal implants in the heel. 
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The device automatically generates two parameters: SOS and broadband ultrasound attenuation 
(BUA). SOS measures the speed at which ultrasound travels through bone, it is calculated by dividing 
the ultrasound transit time by the length of body part studied. BUA is the slope between the 
attenuation of sound signal and its frequency as it travels through the bone and soft tissue. Higher 
SOS and BUA values indicate better bone health (Figure 1, Panel A). Within UKB, if BUA data were 
missing, it was estimated from the SOS measure. We therefore used SOS in this analysis as it was 
always directly measured. In cases where bilateral measurements were available, we used the mean. 
 
Arterial stiffness  
Arterial stiffness is a measure of vascular compliance; increased stiffness indicates adverse 
remodelling of the medial layer and impairment of arterial bio-elastic function. Greater arterial 
stiffness indicates higher risk of atherosclerotic disease and has been validated in a variety of 
settings(17,18). 
 
Arterial stiffness index 
Arterial stiffness index (ASI) is an indirect estimate of large artery stiffness derived from the contour 
of a pulse waveform as it propagates and is reflected within the arterial tree(17). Higher ASI represents 
greater stiffness in the large arteries and is associated with adverse ischaemic cardiovascular 
outcomes(18). Lower ASI indicate greater arterial compliance and better vascular health (Figure 1, 
Panel C). 
 
ASI was measured at the baseline visit using finger photoplethysmography with the PulseTrace PCA2 
(CareFusion, USA) device in accordance with a predefined SOP(19). The participant was seated, and 
restrictive clothing removed from the upper arm. The PulseTrace infrared sensor was clipped onto a 
finger and measurement taken over 10-15s. The device provides a pulse waveform, which 
demonstrates a systolic and diastolic peak, and the time delay between the two peaks (Figure 3). The 
peak-to-peak time (PPT) represents the transit time for the pulse wave from the root of the subclavian 
artery to the point of reflection and back. The stiffer the large arteries, the quicker the transit time 
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(shorter PPT). The path length for the pulse is proportional to the height of the individual, therefore an 
ASI may be calculated by dividing height by PPT (Figure 3). ASI (m/s) was measured for 169,791 
participants at baseline. 
 
Aortic distensibility 
Aortic distensibility (AD) is a direct measure of local arterial stiffness determined by the change in 
aortic cross-sectional area in systole-diastole (i.e. aortic strain) divided by central pulse pressure (CPP 
in mmHg) (20). It is calculated as in Equation 1. Higher AD indicates a more compliant aorta and better 
vascular health (Figure 1, Panel B). 
 






where Amax is the maximal and Amin the minimal aortic lumen area (mm2) 
 
AD was measured on cine CMR images showing transverse cross-sections of the ascending and 
descending aorta throughout the cardiac cycle (Figure 2). A fully automated image analysis workflow 
has been developed and validated on a large subset of UKB studies (n=5,065)(21). The analysis 
pipeline has been propagated to cover the first 20,000 UKB CMR scans. 
 
Cardiovascular outcomes 
We considered outcomes occurring from point of recruitment (2006–2010) to the latest UKB censor 
dates (mortality outcomes: 31/01/2018, incident AMI: 31/03/2017) giving follow-up duration of 7-12 
years. IHD mortality was defined as primarily cause of death attributed to IHD on death registration 
documents. Incident AMI was derived from algorithmically defined outcomes, which includes HES 
and death register data(22); AMIs occurring after the baseline visit were considered. 
 
 8 
Definition of covariates 
Age, sex, and ethnicity were taken as recorded at baseline. Smoking and alcohol intake were defined 
according to self-report at baseline. Material deprivation is recorded in the UKB as the Townsend 
index. We calculated a continuous measure for level of physical activity in metabolic equivalent 
(MET) minutes/week by weighting different types of activity (walking, moderate or vigorous) by its 
energy requirements as per the International Physical Activity Questionnaire (IPAQ) study(23). 
Hypertension, diabetes, hypercholesterolaemia, and menopause were defined based on self-report at 
baseline. Body mass index was calculated from height and weight recorded at baseline. The following 
serum biochemistry measures (from bloods collected at the baseline visit) were considered as 
potential mediators: C Reactive Protein (CRP), Creatinine, Vitamin D, Calcium, Alkaline 
Phosphatase (ALP), Insulin-like Growth Factor 1 (IGF1), Sex Hormone Binding Globulin (SHBG), 
Testosterone, Testosterone/SHBG, Oestradiol, Phosphate, Cystatin C. 
 
Statistical analysis  
Statistical analysis was performed using R studio version 3.6.0 [https://www.R-project.org/] and Stata 
version 14 [StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP]. Continuous variables are summarised as mean (standard deviation) for normally distributed 
parameters and median [interquartile range (IQR)] for skewed distributions. We used a 1.5× IQR rule 
to remove outliers from the SOS, ASI, and AD variables. 
 
We tested the association of SOS with the ischaemic cardiovascular outcomes separately for men and 
women using competing risk regression models(24). We report subdistribution hazard ratios (SHR) per 
one standard deviation increase in SOS with the corresponding 95% confidence intervals (CIs) and p-
values. We next considered the association of SOS with measures of arterial compliance (ASI, AD) 
using multivariate linear regression models adjusting for age, exercise, smoking, material deprivation, 
alcohol intake, hypercholesterolaemia, diabetes, and hypertension. Results are presented as standard 
deviation change in vascular measure per one standard deviation increase in SOS, tested separately by 
sex. We checked for non-linearity of this relationship using restricted cubic splines. In addition, we 
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performed subgroup analyses by menopause (women only), smoking status, diabetes, and obesity. We 
tested whether associations of SOS with vascular compliance explained relationships with ischaemic 
cardiovascular outcomes. 
 
Finally, we evaluate the mediating effect of a range of blood biomarkers (CRP, Creatinine, Vitamin 
D, Calcium, ALP, IGF1, SHBG, Testosterone, Testosterone/SHBG, Oestradiol, Phosphate, Cystatin 
C) and cardiometabolic morbidities (hypertension, diabetes, hypercholesterolaemia) selected based on 
evidence outlined in existing cardiovascular disease literature. The mediating effect of each mediator 
was first tested individually, if a significant effect was detected (p<0.003, corrected for 15 mediators), 
the mediator was taken forward for multiple mediation analysis. Independent indirect effects were 
calculated for each mediator as described by Van Der Weele and Vansteelandt(25). Confidence 
intervals were constructed using bootstrap re-sampling. We thus calculate the direct and indirect 






Complete data for SOS and ASI were available for 71,949 men and 87,593 women (Table 1). 
Average age was 58 [50-63] years. Rates of smoking, hypertension, diabetes, and high cholesterol 
were 28.0%, 5.6%, and 19.7% respectively. Men had poorer cardiometabolic profile compared to 
women. The majority of women (73.0%) were post-menopause. There were 18,229 participants with 
SOS and AD data; their baseline characteristics are summarised in Supplementary Table 1. 
 
Association of SOS with measures of arterial stiffness 
In fully adjusted linear regression models, higher SOS was associated with lower ASI; the 
relationship appeared significant and of similar magnitude for both men and women (Table 2). Higher 
SOS was associated with greater AD at the ascending aorta in fully adjusted models for women, but 
not for men. Higher SOS was associated with greater AD at the descending aorta in fully adjusted 
models for men, but not for women. There was no evidence of non-linearity for these relationships 
(Supplementary Table 2). There were no significant differences in the relationships between men and 
women. 
 
In stratified analyses, we did not find a differential pattern of association by menopause (Table 3). 
Higher SOS was associated with lower ASI in pre- and post-menopausal women. There was loss of 
statistical significance in the AD associations, likely due to small sample size, again with no evidence 
of differential relationship by menopause. 
 
Association of SOS with measures of arterial stiffness by smoking status, diabetes, and BMI 
We found no significant difference in pattern of associations in subgroup analysis by smoking status 
(Supplementary Table 3). Subgroup analysis by diabetes appeared to show a differential relationship 
with greater effect in non-diabetics; the interaction term was significant for the relationship between 
SOS and ASI in men (p=0.012) (Supplementary Table 4). With regards BMI (Supplementary Table 
5), there appeared to be differential effect of SOS on ASI in men with BMI in the normal or 
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overweight categories vs those in the obese category with significant interaction term (p=0.0008). 




We considered the role of mediators in the relationship between SOS and ASI as this appeared the 
most consistent relationship in previous analyses. We considered, separately for men and women, 
potential mediating effects of the following variables: CRP, Creatinine, Vitamin D, Calcium, ALP, 
IGF1, SHBG, Testosterone, Testosterone/SHBG, Oestradiol, Phosphate, Cystatin C, hypertension, 
diabetes, and hypercholesterolaemia. We first checked the mediating effect of each variable 
individually (Supplementary Tables 6 and 7); variables with significant mediated effects were taken 
forward for multiple mediation analysis. In the final models, we included variables that had 
statistically significant effects in the multiple mediator model (Supplementary Tables 8 and 9). 
 
In multiple mediation analysis, biomarkers relating to bone mineralisation appeared important for 
both men and women. For men, ALP, phosphate, and vitamin D accounted for 7.5%, 4.6%, and 3.2% 
of the observed effect. In women, ALP and phosphate accounted for 9.6% and 13.2% of the observed 
effect. CRP accounted for 6.1% of the mediated effect in men and -8.6% in women. SHBG had an 
important suppressing effect for both men and women as adjustment for this variable increased the 
effect by 17.14% and 19.55% respectively. 
 
In men the overall effect was mediation i.e. the magnitude of the main exposure-outcome relationship 
effect was reduced by adjustment for the mediators. In the women the effect was one of suppression 
rather than mediation as the magnitude of the exposure-outcome relationship increased when we 
added the potential mediators. The association between ASI and SOS remained significant with all the 
mediators in the model. 
 
Association of SOS with ischaemic cardiovascular outcomes 
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SOS was available for 477,683 participants at baseline. We considered association with IHD mortality 
and incident AMI for this cohort (Table 4); baseline characteristics are summarised in Supplementary 
Table 10. Follow-up time for mortality was 2,342,445 person years for women and 1,888,767 for 
men. There were 388 IHD deaths in women (rate=0.17 per 1000 person years) and 1,722 (rate=0.91 
per 1000 person years) in men. Follow-up time for incident AMI was 2,123,170 person years for 
women and 1,659,850 person years for men. During this time, there were 2,415 AMI events in 
women (rate=1.14 per 1000 person years) and 5,616 events (rate=3.38 per 1000 person years) in men. 
 
In crude models including age only, higher SOS was associated with significantly reduced hazard of 
both incident AMI and IHD mortality in men, but not in women. There was loss of significance for 
the relationship with incident AMI with addition of exercise, material deprivation, and alcohol to the 
model. The negative association with IHD mortality remained significant in men in this model and in 
a further model additionally including hypertension, hypercholesterolaemia, and diabetes. In this fully 
adjusted model, for men, one standard deviation increase of SOS was associated with 14% lower 
hazard of IHD mortality [SHR 0.86 (0.75-1.00), p-value 4.0×10-7]. 
 
We tested whether the relationship of SOS with IHD mortality may be explained by observed 
associations of the former with ASI. Addition of ASI as covariate to competing risk models did not 
alter the association of greater SOS with lower IHD mortality in men, and no association in women. 




Summary of study findings 
Our findings support association of higher SOS with lower arterial compliance (higher AD, lower 
ASI), that is, that better bone health is associated with better heart health. The relationship appeared 
consistent in men and women and by menopause status. There was no clear differential relationship 
by smoking status, diabetes, or BMI. A range of blood biomarkers were considered as potential 
mediators of the association between SOS and ASI; the mediation pattern appeared different for men 
and women and these markers did not adequately explain the observed associations. Higher SOS was 
associated with lower IHD mortality in men, but not in women. This relationship was not attenuated 
with addition of ASI to models, suggesting mediation through independent mechanisms. In summary, 
higher SOS was associated with better vascular health by ASI and AD and with lower IHD mortality 
in men; underlying mechanisms are complex and likely vary by sex. 
 
Strengths and limitations 
The large, broad population sample in UKB permitted investigation of sex-specific, and in women 
menopause status specific, relationships using validated measures of bone and cardiac health, 
incorporating a wide range of covariates and mediators. The age range in UKB was limited to 40-69 
years at recruitment, as such, our results may not be applicable to younger or older ages. There is 
limited information in terms of the performance characteristics of the heel ultrasound device used in 
UK Biobank. Several instruments of the same type and same software version were used across the 
centres, but coefficients of variation and long-term stability data not available currently. If anything, 
inability to accommodate these factors is likely to add noise and thus bias towards the null rather than 
generate any spurious relationships. Finally, we cannot exclude the possibility of residual 
confounding due to the observational design of the study, and it should be recognised that although 
mediation analysis partitions variance in the associations, we cannot conclude causal relationships 
directly from this analysis. 
 
Comparison with existing literature 
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Several smaller studies have investigated the relationship between bone quality and arterial stiffness 
made by pulse waveform analysis, but none using AD. In general, there is under-representation of 
men and pre-menopausal women and there are scant data through which to infer sex or menopausal 
status specific effects. A number of studies have been conducted in small highly selective cohorts 
with specific risk profiles, which limits the generalisability of their findings and has the inherent 
potential to introduce bias. 
 
Consistent with our findings, in a study of 7,865 Japanese men and women, Hirose et al.(26) report a 
significant association between better bone quality on calcaneal QUS and lower arterial stiffness by 
pulse wave velocity (PWV), with the relationship appearing stronger for post-menopausal women. 
Avramovski et al.(27) and Zhang et al(28) also report significant negative associations between BMD 
and arterial stiffness. Distinctions between men and women or menopause status were not considered, 
perhaps due to sample size limitations. These findings are consistent with results from small cohorts 
of Korean(29) and Turkish women(30).  In a study of 633 individuals, Giallauria et al.(31) report a 
significant association between higher bone quality assessed by computed tomography and lower 
arterial stiffness by PWV for women, but not for men. 
 
Several studies investigated the relationship between bone quality and vascular health in populations 
with specific risk profiles. For instance, Masugata et al.(32) demonstrated a negative association 
between BMD and arterial stiffness in 52 hypertensive men and women. Interestingly, Li et al.(33) 
documented a negative association between BMD and arterial stiffness by PWV in hypertensive men 
(n=355), but not in a comparator group without hypertension. Similarly, Li et al.(34) reported a 
significant negative association between lumbar spine BMD and arterial stiffness by PWV in 334 men 
with silent brain infarction, but not in 368 matched controls. Van Dijk et al.(35) identified no 
association between arterial stiffness measures and BMD or QUS parameters in 519 older men and 
women with hyperhomocystinaemia. The findings to date from these generally small studies are 
therefore somewhat variable, but in general support the notion of positive associations between bone 
and cardiovascular health. 
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Our findings, in the largest sample studied to date, confirm the association of better bone quality 
(higher SOS) with lower arterial compliance (lower ASI, higher AD) with consistent relationships by 
sex and menopause status. 
 
A number of studies have examined the relationship between serum markers of bone metabolism and 
arterial stiffness. In a study of the relationship between plasma regulators of bone metabolism in 
1,003 individuals with type 2 diabetes, Sharif et al.(36) identify significant association between higher 
levels of plasma osteopontin and greater arterial stiffness. In a study of 144 post-menopausal women, 
Albu et al.(37) identify significant association between higher plasma osteoprotegerin levels and 
greater arterial stiffness on PWV, but not with osteopontin (as per Sharif et al.(36)), suggesting possible 
differences in pathophysiology in men and women. However, given that osteoprotegin and 
osteopontin have been implicated directly in vascular pathology as well as bone metabolism, such 
findings do not necessarily demonstrate direct bone-heart mechanisms(38). Indeed, such observations 
clearly demonstrate the complexity in these relationships and the difficulty in elucidating specific 
mechanisms in bone versus those in the vascular endothelium at the whole organ level. Our analysis 
of the effect of a range of blood biomarkers in mediating the relationship between SOS and ASI also 
suggested differences in mechanistic pathways in men and women. 
 
Our finding of association of higher SOS with lower IHD mortality in men was consistent with 
multiple previous reports of association of lower BMD with cardiovascular mortality outcomes, 
which, similar to our findings, appeared stronger in men(39–41). Whilst several small studies in select 
populations of older women, appear to show an inverse association between QUS measures of bone 
health and cardiovascular mortality (without specificity for IHD mortality) (42,43), these findings are 
not replicated in larger studies(44). Consistent with our findings, in a study of 5,816 older women, 
Bauer et al.(44) do not report a significant association between BMD and cardiovascular mortality over 
five years of prospective follow up. Interestingly, in the present study, the observed inverse 
association between SOS with IHD mortality in men was not explained by association of higher SOS 




Our findings support a positive association between bone and vascular health measures which is 
consistent in men and women and with menopause. The association of higher SOS with lower IHD 
mortality appeared significant for men and was not explained by associations with arterial stiffness. 
The underlying pathophysiology of the bone heart axis is complex and multifaceted and likely varies 
in men and women. Further research into potential mechanistic pathways is needed.  
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Table 1. Baseline participant characteristics (Baseline sample)  






Age 58 [50-63] 59 [51-64] 58 [50-63] 
Ethnicity (White Caucasian) 145,627 (91.9%) 65,804 (92.2%) 79,823 (91.6%) 
Townsend deprivation score -1.8 [-3.4 to 0.8] -1.8 [-3.4 to 0.8] -1.8 [-3.4 to 0.7] 
Body mass index kg/m2 26.7 [24.1 to 29.8] 27.2 [24.9 to 29.9] 26.1 [23.4 to 29.8] 
Current smoking 16,085 (10.1%) 8,637 (12.0%) 7,448 (8.5%) 
Regular alcohol use 67,664 (42.5%) 36,478 (50.9%) 31,186 (35.7%) 
Physical activity (metabolic 
equivalent minutes/week) 
1,891 [874 to 3,786] 1,908 [864 to 3,930] 1,866 [878 to 3,666] 
Multimorbidity (number of non-
cancer illnesses) 
2.0 [1.0 to 3.0] 2.0 [1.0 to 3.0] 2.0 [1.0 to 3.0] 
Hypertension  44,626 (28.0%) 23,676 (32.9%) 20,950 (23.9%) 
Diabetes 8,981 (5.6%) 5,351 (7.4%) 3,630 (4.1%) 
Hypercholesterolaemia 31,465 (19.7%) 18,571 (25.8%) 12,894 (14.7%) 
Post-menopausal – – 53,940 (73.0%) 
Arterial stiffness index (m/s) 9.0 [6.9 to 11.2] 9.8 [7.8 to 11.8] 8.3 [15.3 to15.7] 
Speed of sound (102m/s) 15.5 (0.3) 15.6 (0.3) 15.5 (0.3) 
 
Table 1 footnote: Data based on information collected at baseline assessment. Continuous variables presented 
as median [interquartile range] or mean (standard deviation). Discrete data presented as frequencies 
(percentages).   
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Table 2. Linear regression models showing association of SOS with measures of arterial stiffness 
in men and women 
  
Model 1: Age 
Model 2: Age, exercise, 
smoking, deprivation, 
alcohol 
Model 3: Model 2+ 
hypercholesterolaemia, 
diabetes, hypertension 
 ASI  
Men B (95% CI) -0.030 (-0.037, -0.023) -0.021 (-0.028, -0.013) -0.020 (-0.028, -0.012) 
n=71,949 p-value 4.8×10-17* 1.5×10-7* 2.6×10-7* 
Women B (95% CI) -0.027 (-0.034, -0.021) -0.024 (-0.031, -0.016) -0.026 (-0.033, -0.018) 
n=87,593 p-value 5.6×10-16* 6.0×10-10* 2.8×10-11* 
P value for interaction  0.605 0.541 0.307 
 AD (ascending aorta) 
Men B (95% CI) 0.018 (0.000, 0.036) 0.017 (-0.002, 0.036) 0.017 (-0.002, 0.036) 
n=8,767 p-value 0.046 0.085 0.085 
Women B (95% CI) 0.025 (0.008, 0.042) 0.020 (0.000, 0.039) 0.020 (0.000, 0.039) 
n=9,462 p-value 0.004* 0.045* 0.043* 
P value for interaction  0.588 0.846 0.829 
 AD (descending aorta) 
Men B (95% CI) 0.040 (0.021-0.059) 0.037 (0.018, 0.057) 0.037 (0.017, 0.056) 
n=8,767 p-value 2.2×10-5* 0.0002* 0.0002* 
Women B (95% CI) 0.017 (-0.000, 0.035) 0.019 (-0.001, 0.039) 0.019 (-0.000, 0.039) 
n=9,462 p-value 0.057 0.063 0.054 
P value for interaction  0.081 0.194 0.217 
Table 2 footnote: ASI: arterial stiffness index; AD: aortic distensibility; B: beta coefficient; CI: confidence 
interval; SOS: speed of sound. B= increase (number of SDs) in outcome for a 1 SD increase in SOS. *indicates p-value 
<0.05.  
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Table 3. Linear regression models showing association of SOS with measures of arterial stiffness 
in women stratified by menopause status 
  Model 1: Age Model 2: Age, exercise, 
smoking, deprivation, 
alcohol. 
Model 3: Model 2+ 
hypercholesterolaemia, 
diabetes, hypertension  
 ASI  
Pre-menopause B (95% CI) -0.026 (-0.041, -0.011) -0.025 (-0.041, -0.008) -0.025 (-0.042, -0.009) 
n=33,653 p-value 0.0008* 0.003* 0.003* 
Post-menopause B (95% CI) -0.019 (-0.028, -0.010) -0.015 (-0.025, -0.005) -0.018 (-0.028, -0.007) 
n=53,940 p-value 4.9×10-5* 0.005* 0.0009* 
P value for interaction  0.433 0.327 0.449 
 AD (ascending aorta) 
Pre-menopause B (95% CI) 0.016 (-0.017, 0.049) 0.012 (-0.024, 0.048) 0.012 (-0.024, 0.048) 
n=4,333 p-value 0.338 0.522 0.516 
Post-menopause B (95% CI) 0.013 (-0.011, 0.037) 0.011 (-0.016, 0.038) 0.012 (-0.015, 0.039) 
n=5,129 p-value 0.288 0.483 0.370 
P value for interaction  0.884 0.964 0.984 
 AD (descending aorta) 
Pre-menopause B (95% CI) 0.003 (-0.029, 0.036) 0.001 (-0.035. 0.036) 0.001 (-0.035, 0.036) 
n=4,333 p-value 0.837 0.973 0.957 
Post-menopause B (95% CI) 0.004 (-0.020, 0.028) 0.008 (-0.019, 0.035) 0.009 (-0.018, 0.035) 
n=5,129 p-value 0.741 0.563 0.513 
P value for interaction  0.977 0.749 0.727 
Table 3 footnote: ASI: arterial stiffness index; AD: aortic distensibility; B: beta coefficient; CI: confidence 
interval; SOS: speed of sound. B= increase (number of SDs) in outcome for a 1 SD increase in SOS. *indicates p-value 
<0.05.  
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Table 4. Competing risk models of the association of SOS with incident AMI and IHD mortality 
n=477,683 
 Model 1: Age Model 2: Age, 
exercise, smoking, 
deprivation, alcohol 
Model 3: Model 2+ 
hypercholesterolaemia, 
diabetes, hypertension 
 Incident AMI 
Men (n=214,410) SHR (95% CI) 0.96 (0.93-0.99) 0.99 (0.96-1.02) 0.99 (0.96-1.02) 
 p-value 0.002* 0.651 0.658 
Women (n=263,273) SHR (95% CI) 0.97 (0.93-1.01) 1.03 (0.97-1.08) 1.00 (0.95-1.05) 
 p-value 0.159 0.352 0.987 
 IHD mortality 
Men (n=214,410) SHR (95% CI) 0.81 (0.77-0.85) 0.86 (0.81-0.91) 0.86 (0.81-0.91) 
 p-value 7.8×10-15* 9.9×10-7* 4.0×10-7* 
Women (n=263,273) SHR (95% CI) 0.92 (0.82-1.02) 0.91 (0.78-1.05) 0.86 (0.75-1.00) 
 p-value 0.093 0.184 0.051 
 
Table 4 footnote: AMI: acute myocardial infarction; ASI: arterial stiffness index; CI: confidence interval; SHR: 
subdistribution hazard ratio; IHD: ischaemic heart disease. *indicates p-value <0.05  
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